Methods and compositions for immunotherapy of B cell involvement in promotion of a disease condition comprising multiple sclerosis
First Claim
1. A method for reducing a pro-multiple sclerosis immune response in an individual, wherein the pro-MS immune response comprises a humoral immune response induced against an epitope comprising terminal alpha 2,6 linked sialic acid on shed antigen, the method comprising administering to the individual a composition comprising an affinity ligand which selectively binds to a B cell determinant, wherein the B cell determinant is selected from the group consisting of CD19, CD20, CD21, CD22, Lym-1, and a determinant expressed only by B cells and not by immune cells other than B cells;
- wherein the B cells targeted by the method and by the composition are nonmalignant B cells, wherein the composition is administered in an amount effective to deplete B cells, and wherein the depletion of B cells results in reducing the pro-multiple sclerosis immune response induced against the epitope comprising terminal alpha 2,6 linked sialic acid.
0 Assignments
0 Petitions
Accused Products
Abstract
Methods are provided for reducing a pro-multiple sclerosis immune response by administering to an individual a composition comprising an affinity ligand which binds to B cell determinant, and which is administered in an amount effective to reduce B cells.
-
Citations
48 Claims
-
1. A method for reducing a pro-multiple sclerosis immune response in an individual, wherein the pro-MS immune response comprises a humoral immune response induced against an epitope comprising terminal alpha 2,6 linked sialic acid on shed antigen, the method comprising administering to the individual a composition comprising an affinity ligand which selectively binds to a B cell determinant, wherein the B cell determinant is selected from the group consisting of CD19, CD20, CD21, CD22, Lym-1, and a determinant expressed only by B cells and not by immune cells other than B cells;
- wherein the B cells targeted by the method and by the composition are nonmalignant B cells, wherein the composition is administered in an amount effective to deplete B cells, and wherein the depletion of B cells results in reducing the pro-multiple sclerosis immune response induced against the epitope comprising terminal alpha 2,6 linked sialic acid.
- View Dependent Claims (18, 19, 20, 21, 22, 23, 24, 25)
-
2-17. -17. (canceled)
-
26. A site-directed method for reducing a pro-multiple sclerosis immune response in an individual, wherein the pro-multiple sclerosis immune response is a humoral immune response induced against an epitope comprising a terminal alpha 2,6 linked sialic acid on shed antigen, the method comprising administering to the individual a composition comprising an affinity ligand, which selectively binds to a B cell determinant, wherein the B cell determinant is selected from the group consisting of CD19, CD20, CD21, CD22, Lym-1, and a determinant expressed only by B cells and not by immune cells other than B cells;
- wherein B cells targeted by the method and by the composition are nonmalignant B cells, wherein the composition is delivered into an access that directly supplies central nervous tissue undergoing demyelination, wherein the composition is administered in an amount effective to deplete B cells, and wherein the depletion of B cells results in reducing the pro-multiple sclerosis immune response induced against the epitope comprising terminal alpha 2,6 linked sialic acid epitope.
- View Dependent Claims (27, 28, 29, 30, 31, 32)
-
33. A method for reducing a pro-multiple sclerosis immune response in an individual, wherein the pro-multiple sclerosis immune response is directed against an epitope comprising terminal alpha 2,6 linked sialic acid contained on shed antigen comprising a glycolipid, the method comprising administering to the individual a composition comprising a monoclonal antibody, wherein the monoclonal antibody binds to a B cell determinant selected from the group consisting of CD19, CD20, CD21, CD22, Lym-1, and a determinant expressed only by B cells and not by immune cells other than B cells;
- wherein B cells targeted by the method and by the composition are nonmalignant B cells, and wherein the composition is administered in an amount effective to deplete B cells such that said pro-MS immune response is reduced.
- View Dependent Claims (34, 35, 36, 37)
-
38. A method for treating inflammation associated with multiple sclerosis, wherein the inflammation is caused by a humoral immune response against a shed antigen comprising an epitope comprising a terminal alpha 2,6 linked sialic acid, the method comprising depleting B cells to inhibit said humoral immune response by administering an amount of a composition effective to deplete B cells and reduce said humoral immune response against the shed antigen, wherein the composition comprises an affinity ligand which binds to a B cell determinant selected from the group consisting of CD19, CD20, CD21, CD22, Lym-1, and a determinant expressed only by the B cells and not by immune cells other than B cells;
- and wherein B cells targeted by the method and by the composition are nonmalignant B cells.
- View Dependent Claims (39, 40, 41, 42, 43, 44)
- 45. A method for reducing a pro-multiple sclerosis immune response comprising administering to an individual an affinity ligand which selectively binds to a B cell determinant of a shed antigen-specific B cell, wherein the B cells are nonmalignant B cells.
Specification